8BN

Tegoprazan

Created:	2021-12-03
Last modified:	2022-01-05

Find Related PDB Entry
1 entries where 8BN is found as a standalone ligand

Help Find related ligands:
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Help

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	47
Chiral Atom Count	1
Bond Count	50
Aromatic Bond Count	16

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	Tegoprazan
Systematic Name (OpenEye OEToolkits)	7-[[(4~{S})-5,7-bis(fluoranyl)-3,4-dihydro-2~{H}-chromen-4-yl]oxy]-~{N},~{N},2-trimethyl-3~{H}-benzimidazole-5-carboxamide
Formula	C₂₀ H₁₉ F₂ N₃ O₃
Molecular Weight	387.38
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	CACTVS	3.385	CN(C)C(=O)c1cc2[nH]c(C)nc2c(O[CH]3CCOc4cc(F)cc(F)c34)c1
SMILES	OpenEye OEToolkits	2.0.7	Cc1[nH]c2cc(cc(c2n1)OC3CCOc4c3c(cc(c4)F)F)C(=O)N(C)C
Canonical SMILES	CACTVS	3.385	CN(C)C(=O)c1cc2[nH]c(C)nc2c(O[C@H]3CCOc4cc(F)cc(F)c34)c1
Canonical SMILES	OpenEye OEToolkits	2.0.7	Cc1[nH]c2cc(cc(c2n1)O[C@H]3CCOc4c3c(cc(c4)F)F)C(=O)N(C)C
InChI	InChI	1.03	InChI=1S/C20H19F2N3O3/c1-10-23-14-6-11(20(26)25(2)3)7-17(19(14)24-10)28-15-4-5-27-16-9-12(21)8-13(22)18(15)16/h6-9,15H,4-5H2,1-3H3,(H,23,24)/t15-/m0/s1
InChIKey	InChI	1.03	CLIQCDHNPDMGSL-HNNXBMFYSA-N

Drug Info: DrugBank

DrugBank ID	DB16690
Name	Tegoprazan
Groups	investigational
Description	Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases.[A234215, A234220] This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time.[A234215, A234220] Tegoprazan’s strong and sustained effect is due to its ability to be slowly cleared from the gastric glands and exertion of effects independent of acid levels.[A234220] It has also been observed to be efficacious independent of food intake.[A234220]
Synonyms	K-CAB CJ-12420 LXI-15028 IN-A001 RQ-00000004 Tegoprazan
Categories	Alimentary Tract and Metabolism Drugs for Acid Related Disorders Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) Gastric Acid Lowering Agents Proton Pump Inhibitors
ATC-Code	A02BC09
CAS number	942195-55-3

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Sodium/Potassium Transporting ATPase	MGKGVGRDKYEPAAVSEQGDKKGKKGKKDRDMDELKKEVSMDDHKLSLDE...	unknown	inhibitor

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682